Sanofi’s later-stage trials hardest hit by COVID-19: Report

Sanofi’s trials and attempts at getting new drugs and vaccines against the pandemic onto the market have been some of the hardest hit by COVID-19.

This is according to a new report out by life science analytics firm GlobalData, which says the French Big Pharma has been “impacted by disrupted clinical trials and lagging vaccine development due to COVID-19.”